Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
ClearBridge Investments Small Cap Growth Strategy Jeffrey Bailin, Aram Green | “Protagonist Therapeutics is a biopharmaceutical company that currently has two internally discovered, clinically derisked drugs likely to launch with their partners in the near future, which we believe offer blockbuster potential — particularly an oral version of a well-adopted injectable mechanism treating a range of immunology and inflammation conditions. The company's pipeline is differentiated by its oral delivery approach, which could significantly improve patient adherence versus injectable alternatives. Both programs have been validated through prior clinical data, reducing development risk. The proximity to commercialization with partners improves capital efficiency and downside protection. We believe upcoming launches represent meaningful value creation opportunities for shareholders. BSD Analysis: Protagonist is a biotech that looks boring until you understand how differentiated its peptide platform really is. The company targets well-validated biology with novel delivery approaches, reducing binary risk compared to moonshot science. Partnerships help validate assets and offset funding risk. Clinical results matter enormously — valuation moves with data, not sentiment. The upside is asymmetric if lead programs continue to hit, especially in large autoimmune indications. Timelines are long and volatility is guaranteed. This is not a revenue story yet — it's an evidence story. For disciplined biotech exposure, Protagonist offers real science with measured ambition. High risk, but not reckless.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
